Convergent Therapeutics Announces Presentations at the 2023 ASCO Genitourinary (GU) Cancers Symposium on its Lead Candidate
2023-02-16
ASCO会议放射疗法
CAMBRIDGE, Mass., Feb. 16, 2023 /PRNewswire/ -- Today, Convergent Therapeutics Inc., a clinical stage biotechnology company, announced the titles of posters evaluating its lead asset, CONV01-α (225Ac−J591), a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to Ac-225 (225Ac), that will be presented at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium happening in a hybrid mode at San Francisco, February 16-18.
The complete list of abstract titles can be found here.
Poster presentations will focus on two ongoing clinical studies, a trials-in-progress update from NCT04506567, and a data update from NCT04946370, that are both currently investigating CONV01-α (225Ac−J591) in patients with progressive metastatic castration-resistant prostate cancer (mCRPC) and are led by Principal Investigator Dr. Scott T. Tagawa, Professor of Medicine in Urology at Weill Cornell Medicine.
Poster Details:
Abstract Number: TPS288
Abstract Title: A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA.
Poster Session: Trials in Progress
Poster Bd #: Q10
Presenter: Jones T. Nauseef, MD, PhD
Abstract Number: 181
Abstract Title: Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591.
Poster Session A: Prostate Cancer
Poster Bd #: F18
Presenter: Michael Philip Sun, MD
Convergent Therapeutics, Inc. is a clinical stage biotechnology company focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology was developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine, and licensed to Convergent by Cornell University. CONV01-α, a monoclonal antibody conjugated to actinium-225 (Ac-225), a radioactive alpha particle emitter, was specifically designed to bind to the prostate-specific membrane antigen (PSMA). A key functional feature of CONV01-α is that once bound to PSMA, it becomes internalized, thereby delivering its powerful radioactive payload directly into prostate cancer cells, minimizing damage to surrounding healthy tissue. CONV01-α would be the first radioantibody approved for the use of Ac-225 in cancer treatment. For more information, please visit www.convergentrx.com and follow us on Twitter and LinkedIn.
Convergent Media Contact
Olipriya Das
Russo Partners, LLC
(646) 942-5588
[email protected]
SOURCE Convergent Therapeutics
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。